10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LIN28B Antibody [Knockout Validated]

Purified Mouse Monoclonal Antibody (Mab)
Catalog # AW5710

Specification

LIN28B Antibody [Knockout Validated] - Product Information

Application	**WB,E**
Primary Accession	Q6ZN17
Reactivity	**Human**
Host	**Mouse**
Clonality	**monoclonal**
Isotype	**IgG1,k**
Antigen Source	**HUMAN**

LIN28B Antibody [Knockout Validated] - Additional Information

Gene ID 389421

Other Names
Protein lin-28 homolog B, Lin-28B, LIN28B, CSDD2

Dilution
WB~~1:500-1:2000

Target/Specificity
This LIN28B antibody is generated from a mouse immunized with a recombinant protein of human LIN28B.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
LIN28B Antibody [Knockout Validated] is for research use only and not for use in diagnostic or therapeutic procedures.

LIN28B Antibody [Knockout Validated] - Protein Information

Name LIN28B

Synonyms CSDD2

Function
Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act

on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation (PubMed:19703396). This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5'- GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let- 7 repression (By similarity). When overexpressed, isoform 1 stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.

Cellular Location
Nucleus. Nucleus, nucleolus. Cytoplasm Note=Predominantly nucleolar (PubMed:22118463). In Huh7 cells, predominantly cytoplasmic, with only a subset of cells exhibiting strong nuclear staining; however, the specificity of the polyclonal antibody used in these experiments has not been not documented (PubMed:16971064).

Tissue Location
Expressed at high levels in the placenta and, at mucher lower, in testis and fetal liver (PubMed:16971064). Isoform 1 is only detected in placenta and in moderately and poorly differentiated hepatocellular carcinoma cells (at protein level). Isoform 2 is detected in fetal liver, non-tumor liver tissues, as well as well- differentiated tumor tissues (at protein level). Tends to be up- regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as in liver, ovarian, and thyroid carcinomas (PubMed:22118463)


LIN28B Antibody [Knockout Validated] - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

LIN28B Antibody [Knockout Validated] - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



All lanes : Anti-LIN28B Antibody at 1:4000 dilution Lane 1: 293 whole cell lysate Lane 2: K562 whole cell lysate Lane 3: HepG2 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 27 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



A single 34.3 kDa band for the HEK293T wild type lysate was observed (3 ug/ml anti- LIN28B) that closed matches the predicted size of 27.1 kDa. The molecular weight discrepancy could be due a post-translationally modified form of the target protein, a splice-variant form of the target protein, or an unrelated protein which shares the antibody-reactive epitope. A single 60.7 kDa band was observed in the knock out lysate (20 ug lane only).

LIN28B Antibody [Knockout Validated] - Background

Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre- let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.

LIN28B Antibody [Knockout Validated] - References

Moss E.G.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Mungall A.J.,et al.Nature 425:805-811(2003).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Guo Y.,et al.Gene 384:51-61(2006).